Regression of HPV-Positive Tumors Treated with a New Listeria monocytogenes Vaccine

Archives of Otolaryngology - Head and Neck Surgery

Volumn 130, Issue 1, 2004, Pages 92-97

  Sewell, Duane A ^a,b   Douven, Dennis ^a   Pan, Zhen Kun ^a   Rodriguez, Alex ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; LISTERIA MONOCYTOGENES ACTA E7 FUSION PROTEIN; PROTEIN ACTA; PROTEIN E7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG SYNTHESIS; GENE CASSETTE; HEAD CANCER; IMMUNE RESPONSE; LISTERIA MONOCYTOGENES; MOUSE; NECK CANCER; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; VACCINATION; WART VIRUS;

ANIMALS; BACTERIAL VACCINES; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; HEAD AND NECK NEOPLASMS; IMMUNOTHERAPY; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0345743494     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.130.1.92     Document Type: Article

References (33)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64, 1.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
3. Couch M, Saunders JK, O'Malley BW Jr, Pardoll D, Jaffee E. Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope. 2003;113:552-556.
4. Chikamatsu K, Reichert TE, Kashii Y, et al. Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice. Int J Cancer. 1999;82:532-537.
5. To WC, Wood BG, Krauss JC, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg. 2000;126:1225-1231.
6. Mineta H, Ogino T, Amano HM, et al. Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res. 1998;18:4765-4768.
7. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344:1125-1131.
8. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer: an association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer. 1997;79:595-604.
9. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
10. Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol. 2000;19:16-28.
11. Tindle RW, Frazer IH. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr Top Microbiol Immunol. 1994;186:217-253.
12. Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995;154:5934-5943.
13. Cirillo JD, Stover CK, Bloom BR, Jacobs WR Jr, Barletta RG. Bacterial vaccine vectors and bacillus Calmette-Guerin. Clin Infect Dis. 1995;20:1001-1009.
14. Weiskirch LM, Paterson Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol Rev. 1997;158:159-169.
15. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90-95.
16. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-1970.
17. Portnoy DA, Chakraborty T, Goebel W, Cossart P. Molecular determinants of Listeria monocytogenes pathogenesis. Infect Immun. 1992;60:1263-1267.
18. Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med. 1995;1:471-477.
19. Pan ZK, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res. 1995;55:4776-4779.
20. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16 J Immunol. 2001;167:6471-6479.
21. Goossens PL, Milon G, Cossart P, Saron MF. Attenuated Listeria monocytogenes as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int Immunol. 1995;7:797-805.
22. Mata M, Paterson Y. Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J Immunol. 1999;163:1449-1456.
23. Rayevskaya MV, Frankel FR. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J Virol. 2001;75:2786-2791.
24. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-26.
25. Tindle RW, Croft S, Herd K, et al. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1-and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin Exp Immunol. 1995;101:265-271.
26. Ikonomidis G, Paterson Y, Kos FJ, Portnoy DA. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J Exp Med. 1994;180:2209-2218.
27. Cooper J, Walker RD. Listeriosis. Vet Clin North Am Food Anim Pract. 1998;14:113-125.
28. Crum NF. Update on Listeria monocytogenes infection. Curr Gastroenterol Rep. 2002;4:287-296.
29. Farber JM, Peterkin PI, Listeria monocytogenes, a food-borne pathogen. Microbiol Rev. 1991;55:476-511.
30. Gellin BG, Broome CV, Bibb WF, et al. The epidemiology of listeriosis in the United States - 1986. Am J Epidemiol. 1991;133:392-401.
31. Dalton CB, Austin CC, Sobel J, et al. An outbreak of gastroenteritis and fever due to Listeria monocytogenes in milk. N Engl J Med. 1997;336:100-105.
32. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect Immun. 2002;70:3592-3601.
33. Lorber B. Listeriosis. Clin Infect Dis. 1997;24:1-9; quiz 10-1.